Stay updated with breaking news from Themis Bioscience. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Adjuvant Capital drew a $75 million anchor investment from the Gates Foundation’s Strategic Investment Fund, as well as significant investment from large drugmakers Merck & Co. and Novartis AG, and such others as the International Finance Corporation and...
Coronavirus Vaccine | How Merck, a vaccine titan, lost the COVID race Merck is now considering a range of options, both in the United States and around the world, mindful that anything it chooses to do would take months to bring to fruition, given the complexity of the manufacturing process New York Times COVID-19 vaccine (Representative image) Katie Thomas From Ebola to HIV to river blindness, American pharmaceutical giant Merck has been on the front lines of the biggest public health emergencies in recent history. So when the company announced in...
Synopsis Last month, Merck exited the vaccine race, abandoning its two candidates after early clinical trials flopped. Now, in addition to testing two experimental COVID-19 drugs, the company says that it’s looking for ways to help competitors supply the world with vaccines. Reuters Merck, which was founded in 1891, has been in the vaccine business for more than 100 years, having developed some of the world’s most well-known vaccines, including those for mumps, hepatitis A and chickenpox. From Ebola to HIV to river blindness, American pharmaceutical giant Merck has been on the front line...
Last month, Merck exited the vaccine race, abandoning its two candidates after early clinical trials flopped
When Merck announced in May that it was a late entrant in the race to develop a COVID-19 vaccine, the American pharmaceutical giant was a popular pick to win.